New study ties weight-loss drugs Wegovy, Ozempic to serious gastrointestinal conditions
Medicines in the same class as popular weight-loss therapies Ozempic and Wegovy may carry an increased risk of pancreatitis, intestinal blockage and stomach paralysis compared to an older obesity drug, Canadian researchers find.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
More News: Canada Health | Eating Disorders & Weight Management | Gastroenterology | Health | Obesity | Pancreatitis | Study | Weight Loss